Second-Line Chemotherapy for Hormone-Refractory Prostate Cancer: Has the Time Come?

This publication has 20 references indexed in Scilit:

• Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583)
  Journal of Clinical Oncology, 2004
• Role of secondary hormonal therapy in the management of recurrent prostate cancer
  Urology, 2003
• Prostate cancer in Italy before and during the ‘PSA era’: survival trend and prognostic determinants
  European Journal Of Cancer Prevention, 2003
• Recent Trends in Prostate Cancer Incidence and Mortality in Southeast England
  European Urology, 2003
• Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing
  Urology, 2002
• Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era
  Urology, 2002
• Antiandrogen Withdrawal Syndrome Associated with Prostate Cancer Therapies
  Drug Safety, 2000
• Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
  Journal of Clinical Oncology, 1999
• STEROID HORMONE WITHDRAWAL SYNDROMES: Pathophysiology and Clinical Significance
  Urologic Clinics of North America, 1997
• Prostate Specific Antigen Decline after Antiandrogen Withdrawal: the Flutamide Withdrawal Syndrome
  Journal of Urology, 1993